Open Access
Subscription or Fee Access
OSTEOPOROSIS FROM HORMONAL REPLACEMENT THERAPY TO BISPHOSPHONATES AND BEYOND: A REVIEW
Abstract
ABSTRACT
Objective: To review the old, current, and emerging agents in pharmacological treatment of
osteoporosis.
Data sources: Published original research work and reviews from 1993 to 31 December 2006 were
searched in English on subjects related to epidemiology, pathophysiology, diagnosis, treatment,
and prevention of osteoporosis.
Study Design: Only articles that emphasize on management.
Data extraction: Online and manual library searches done.
Data synthesis: Data added up and summarized.
Conclusion: Osteoporosis is a serious public health issue. The past 10 years has seen great advances
in our understanding of its epidemiology, pathophysiology, and treatment, and further advances are
rapidly being made. Bisphosphonates represent the biggest advance in the treatment of osteoporosis,
and will probably remain the mainstay of therapy. At the same time other diagnostic and therapeutic
approaches, including biological agents, are likely to become more widespread. Combination
therapy is generally not recommended due to paucity of data concerning antifracture effectiveness,
and, there is currently no definitive answer on the length of treatment with antiresoptive agents.
Objective: To review the old, current, and emerging agents in pharmacological treatment of
osteoporosis.
Data sources: Published original research work and reviews from 1993 to 31 December 2006 were
searched in English on subjects related to epidemiology, pathophysiology, diagnosis, treatment,
and prevention of osteoporosis.
Study Design: Only articles that emphasize on management.
Data extraction: Online and manual library searches done.
Data synthesis: Data added up and summarized.
Conclusion: Osteoporosis is a serious public health issue. The past 10 years has seen great advances
in our understanding of its epidemiology, pathophysiology, and treatment, and further advances are
rapidly being made. Bisphosphonates represent the biggest advance in the treatment of osteoporosis,
and will probably remain the mainstay of therapy. At the same time other diagnostic and therapeutic
approaches, including biological agents, are likely to become more widespread. Combination
therapy is generally not recommended due to paucity of data concerning antifracture effectiveness,
and, there is currently no definitive answer on the length of treatment with antiresoptive agents.
Refbacks
- There are currently no refbacks.
